In recent years, berberine has increasingly appeared in the public sphere as a "natural way" to improve metabolism. In social media, it is sometimes compared to incretin drugs and even referred to as ...

Often labeled a “natural Ozempic,” berberine is widely discussed as a metabolic aid. Yet research suggests its influence may ...

A case series reports dysesthesia and allodynia in patients treated with semaglutide and tirzepatide, suggesting a possible dose related to sensory adverse effect.

Lean Drops, an innovative liquid dietary supplement targeting metabolic function and appetite regulation, has officially ...

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. | Eli Lilly—which has already staged multiple efforts in ...

Q4 2025 earnings call: nimacimab + semaglutide data, higher-dose expansion, Halozyme SC plans, 2026 catalysts—read now.

AbbVie (NYSE:ABBV) reported positive Phase 3 results for risankizumab in Crohn's disease, supporting a potential expansion of its use in this condition. The company also released encouraging ...

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts;Received written FDA Type C meeting minutes ...

Eli Lilly LLY, a dominant player in the global obesity market, derives most of its revenues from its blockbuster GLP-1 medicines, Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Despite ...

A once-weekly amylin analog conferred up to 10.7% weight loss at 42 weeks among adults with overweight or obesity and featured a safety profile similar to placebo, according to topline results from ...